Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Supernus Pharmaceuticals, Inc. currently loses $27.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 4 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Supernus Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, with preliminary results reported on Aug. 3, 2026. Revenue rose 32.4% to about $219.1 million, above the roughly $205.3 million consensus by 6.7%, while adjusted EPS of $0.54 topped the $0.42 estimate by 27.8% even as it fell 40.7% from $0.91 a year ago. Gross profit came in at about $185.4 million, with gross margin near 85%, and operating cash flow was negative about $4.8 million. Net product sales, the largest line, increased 4.9% to roughly $165.7 million; within that, Qelbree climbed 15.1% to about $89.2 million, and royalty, licensing and other revenue jumped 141.3% to about $18.0 million. Consensus for the next period calls for EPS of $0.66 on revenue of $217.8 million.
Next report — what to expect
Supernus Pharmaceuticals, Inc. (SUPN) is set to report on November 3, 2026. The next-period consensus calls for EPS of $0.615 on revenue of $218.3 million. For trailing context, revenue grew +32.4% year over year last quarter. SUPN has beaten EPS in 8 of 8 most recent quarters.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. develops and commercializes central nervous system medicines in the healthcare sector and trades on the NASDAQ under SUPN. Its portfolio spans treatments for epilepsy, ADHD, Parkinson's disease, and other neurologic conditions, and the company recorded $719.0 million of revenue in FY2025.
Today's Snapshot
The day ended with SUPN 3.3% lower at 40.70, in line with a weaker sector. SUPN reports earnings on 29 October.
Trading Volume
Above 10d avg 1.1M
1.1M
vs S&P 500 Today
Underperforming Market
-2.74%
Updated: October 23, 2026 at 20:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$41.06 - $46.53Sell
- RSI (14)44.49Neutral
- Stochastic %K (14, 3, 3)64.51Neutral
- MACD Level (12, 26)-0.71Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.